Abstract
Purpose :
To report the patient characteristics and treatment outcomes in 15 cases of orbital lymphangioma.
Methods :
In our study, patients with orbital lymphangioma diagnosed based on clinical, radiologic, or histologic findings between 1996 and 2013 were enrolled. Patients' charts were retrospectively reviewed to analyze clinical courses and treatment options.
Results :
Two patients without compromised vision were treated by corticosteroids. One patient with surperficial lymphangioma only responded well with surgical excision. Five patients underewent surgical volume reduction (one with prior aspiration of blood) with satisfying outcome. However, six patients suffered from recurrence after surgical excision. Two of them received more surgeries, and three of them became stable after receiving intralesional injection of a sclerosant. One of them need complicated treatment due to intra- cranial involvement. The more the recurrence times, the worse the visual outcome.
Conclusions :
Orbital lymphangioma that does not compromise vision can be treated medically. Patients with threatened vision should be treated by interventions such as aspiration of blood, surgical excision or intralesional injection of a sclerosant. Sclerosing therapy is an effective and rather safe treatment for orbital lymphagioma.
This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.